Market Closed -
Hong Kong S.E.
04:08:07 2024-05-09 am EDT
|
5-day change
|
1st Jan Change
|
5.17
HKD
|
+3.19%
|
|
+11.66%
|
-24.96%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
14,626
|
18,696
|
21,794
|
12,432
|
9,563
|
-
|
-
|
Enterprise Value (EV)
1 |
11,830
|
14,035
|
14,349
|
12,432
|
-252.3
|
-2,601
|
-9,858
|
P/E ratio
|
-23.6
x
|
-249
x
|
-20.1
x
|
-16.9
x
|
-11.6
x
|
-18.6
x
|
-87.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10,723
x
|
17.9
x
|
34.8
x
|
16.8
x
|
11.1
x
|
7.23
x
|
5.61
x
|
EV / Revenue
|
8,673
x
|
13.5
x
|
22.9
x
|
16.8
x
|
-0.29
x
|
-1.97
x
|
-5.78
x
|
EV / EBITDA
|
-21.6
x
|
-93.6
x
|
-20
x
|
-
|
0.35
x
|
4.3
x
|
23.8
x
|
EV / FCF
|
-27.9
x
|
9,815
x
|
-17.8
x
|
-
|
0.38
x
|
11.7
x
|
129
x
|
FCF Yield
|
-3.58%
|
0.01%
|
-5.61%
|
-
|
264%
|
8.52%
|
0.77%
|
Price to Book
|
3.54
x
|
3.34
x
|
2.8
x
|
-
|
1.35
x
|
1.51
x
|
1.62
x
|
Nbr of stocks (in thousands)
|
1,289,165
|
1,499,673
|
1,764,321
|
1,763,130
|
1,760,932
|
-
|
-
|
Reference price
2 |
11.35
|
12.47
|
12.05
|
6.262
|
4.777
|
4.777
|
4.777
|
Announcement Date
|
3/26/21
|
3/22/22
|
3/27/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.247
|
1.364
|
1,043
|
625.4
|
738.5
|
862.1
|
1,322
|
1,705
|
EBITDA
1 |
-
|
-547.5
|
-150
|
-715.8
|
-
|
-712.8
|
-605.3
|
-414.4
|
EBIT
1 |
-
|
-559
|
-182.5
|
-777.3
|
-701.5
|
-796
|
-700.1
|
-477.9
|
Operating Margin
|
-
|
-40,981.38%
|
-17.5%
|
-124.29%
|
-94.98%
|
-92.33%
|
-52.96%
|
-28.03%
|
Earnings before Tax (EBT)
1 |
-
|
-464.3
|
-20.12
|
-893.7
|
-644.2
|
-694
|
-493.2
|
-277.6
|
Net income
1 |
-
|
-463.8
|
-64.54
|
-886.6
|
-631.3
|
-681.6
|
-484.5
|
-278.3
|
Net margin
|
-
|
-34,002.42%
|
-6.19%
|
-141.76%
|
-85.47%
|
-79.06%
|
-36.65%
|
-16.32%
|
EPS
2 |
-9.320
|
-0.4800
|
-0.0500
|
-0.6000
|
-0.3700
|
-0.4120
|
-0.2565
|
-0.0544
|
Free Cash Flow
1 |
-
|
-423.5
|
1.43
|
-804.5
|
-
|
-665
|
-221.7
|
-76.31
|
FCF margin
|
-
|
-31,049.41%
|
0.14%
|
-128.64%
|
-
|
-77.14%
|
-16.77%
|
-4.47%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/20
|
3/26/21
|
3/22/22
|
3/27/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
0.748
|
0.616
|
101.7
|
941.4
|
246
|
195.7
|
183.8
|
379.4
|
-
|
159.8
|
201.2
|
361
|
181.6
|
202.1
|
383.8
|
208
|
224.8
|
432.8
|
486.4
|
729.6
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-212.2
|
-
|
-354.9
|
-397.6
|
-232.6
|
-379.7
|
-
|
-
|
-
|
-366.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-208.76%
|
-
|
-144.28%
|
-203.24%
|
-126.57%
|
-100.06%
|
-
|
-
|
-
|
-101.48%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-0.1600
|
0.1100
|
-0.3100
|
-
|
-
|
-0.2900
|
-0.2500
|
-0.0600
|
-
|
-0.1200
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/21/20
|
3/26/21
|
8/27/21
|
3/22/22
|
8/21/22
|
11/13/22
|
3/27/23
|
3/27/23
|
8/29/23
|
11/13/23
|
3/28/24
|
3/28/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
2,796
|
4,660
|
7,445
|
-
|
9,816
|
12,165
|
19,421
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-424
|
1.43
|
-805
|
-
|
-665
|
-222
|
-76.3
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-1.14%
|
-13.4%
|
-
|
-10.7%
|
-8.96%
|
-7.92%
|
ROA (Net income/ Total Assets)
|
-
|
-13%
|
-1.08%
|
-10%
|
-
|
-7.7%
|
-4.3%
|
-5.8%
|
Assets
1 |
-
|
3,577
|
5,976
|
8,860
|
-
|
8,853
|
11,266
|
4,798
|
Book Value Per Share
2 |
-
|
3.210
|
3.740
|
4.310
|
-
|
3.530
|
3.160
|
2.960
|
Cash Flow per Share
2 |
-
|
-0.2200
|
0.0900
|
-0.3800
|
-
|
-0.1900
|
-
|
-
|
Capex
1 |
-
|
251
|
166
|
239
|
-
|
143
|
187
|
153
|
Capex / Sales
|
-
|
18,401.39%
|
15.88%
|
38.21%
|
-
|
16.63%
|
14.15%
|
8.97%
|
Announcement Date
|
3/18/20
|
3/26/21
|
3/22/22
|
3/27/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
4.777
CNY Average target price
8.944
CNY Spread / Average Target +87.25% Consensus |
1st Jan change
|
Capi.
|
---|
| -24.96% | 1.28B | | +2.97% | 108B | | +10.21% | 105B | | +1.57% | 23.46B | | -12.77% | 21.72B | | -7.05% | 18.64B | | -37.64% | 17.45B | | -6.50% | 17.19B | | +6.00% | 13.99B | | +37.20% | 12.53B |
Bio Therapeutic Drugs
|